David M. Kendall will join Mannkind Corporation as chief medical officer, beginning Feb. 12, the company announced Tuesday in a news release.
In his new position, Kendall will assume full responsibility for leading Mannkind’s scientific research, clinical development, regulatory and medical affairs activity. He will report directly to CEO Michael Castagna, Pharm.D., and will join the company’s executive leadership team.
“David is a world renowned diabetes expert and represents an important addition to our executive leadership team,” Castagna said in the release. “His extensive experience in diabetes research, development, and clinical care in both U.S. and international markets, will be instrumental in helping us achieve the growth potential that we believe Afrezza clearly possesses.”
Most recently, Kendall served as research physician and vice president of global medical affairs for Lilly Diabetes. With Mannkind, Kendall will be based in Westlake Village.
“I’m thrilled to join MannKind and look forward to being part of a company that has the potential to transform the lives of so many people that are living with diabetes,” Kendall said.
Mannkind focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Online: www.mannkindcorp.com.
